184 related articles for article (PubMed ID: 22527669)
21. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
[TBL] [Abstract][Full Text] [Related]
23. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
24. Hormone naïve prostate cancer: predicting and maximizing response intervals.
Moul JW
Asian J Androl; 2015; 17(6):929-35; discussion 933. PubMed ID: 26112479
[TBL] [Abstract][Full Text] [Related]
25. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
26. Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study.
Mytilekas VK; Papaefstathiou E; Koukourikis P; Ouzounidis X; Kazantzidis S; Hatzimouratidis K
Investig Clin Urol; 2023 Nov; 64(6):572-578. PubMed ID: 37932568
[TBL] [Abstract][Full Text] [Related]
27. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
28. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
[TBL] [Abstract][Full Text] [Related]
29. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
Crawford ED; Twardowski PW; Concepcion RS; Hafron JM; Harris RG; Moul JW; Gordan LN; Petrylak DP; Atkinson SN; Boldt-Houle DM; Keane TE; Higano CS; Henderson RJ; Kader AK; Hussain MH; Shore ND
J Urol; 2020 Apr; 203(4):743-750. PubMed ID: 31580749
[TBL] [Abstract][Full Text] [Related]
31. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
[TBL] [Abstract][Full Text] [Related]
32. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
33. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
34. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
35. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
36. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
37. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
Kirby RS; Fitzpatrick JM; Clarke N
BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
[TBL] [Abstract][Full Text] [Related]
38. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
40. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
